Ashvattha Therapeutics

The firm's central business is the development of Hydroxyl Dendrimer Therapeutics (HDTs), a form of nanomedicine designed to traverse tissue barriers and selectively target activated immune cells in areas of inflammation. This targeted drug delivery platform aims to link known small molecule drugs to the HDs, enabling precise delivery and sustained effects in diseased tissues, thereby improving efficacy and reducing side effects. Ashvattha's business model involves in-house research and development, funded by significant venture capital, and strategic licensing partnerships for commercialization. The company has raised approximately $180 million through multiple funding rounds, including a $69 million Series B round in April 2022 and a $50 million extension in January 2025. A key partnership includes an exclusive licensing agreement with Huadong Medicine for the development and commercialization of its pipeline assets in Asia.

Ashvattha is advancing a pipeline of clinical-stage candidates targeting unmet needs in ophthalmology, neurology, and inflammatory diseases. A leading product candidate, migaldendranib (MGB), is a subcutaneously administered treatment for neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). This at-home treatment has shown promising interim Phase 2 results in reducing treatment burden for patients who might otherwise require frequent injections in both eyes. Other pipeline assets include therapeutics for neuroinflammation and oncology, with some candidates also being developed as imaging agents to track neuroinflammation in conditions like multiple sclerosis. The company's strategy focuses on conditions where their technology can offer a distinct advantage over current standards of care, such as providing a systemic, at-home alternative to frequent in-clinic injections.